Clinical Trial Update: Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluating hepatic artery infusion chemotherapy in combination with durvalumab for advanced hepatocellular carcinoma has completed and posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2026-02-25